Astrana Health (ASTH) Revenue Soars 53%

By Philip Seaworth • Sunday, May 11 15:24 • Permanent Link

Astrana Health, Inc. recently released its 10-Q report for the first quarter of 2025, providing insights into the company's financial performance and operations. Here are the key highlights from the report:

Revenue: Total revenue for the first quarter of 2025 was $620.4 million, a significant increase of 53% compared to $404.4 million in the same period in 2024. Capitation revenue saw a substantial increase of $218.0 million, primarily due to recent acquisitions within the Care Partners segment and enrollees transitioning to full risk through the company’s Restricted Knox-Keene plans.

Operating Expenses: Expenses related to cost of services, excluding depreciation and amortization, were $549.1 million for the first quarter of 2025, representing a 66% increase from $330.4 million in the same period in 2024. General and administrative expenses totaled $43.9 million, up by 13% from $38.7 million in the first quarter of 2024.

Adjusted EBITDA and Adjusted EBITDA Margin: Adjusted EBITDA for the first quarter of 2025 was $36.4 million, down from $42.2 million in the same period in 2024. The company's Adjusted EBITDA margin, calculated as Adjusted EBITDA over total revenue, was not provided in the report.

Segment Financial Performance: Care Partners segment revenue for the first quarter of 2025 was $601.0 million, a 57% increase from $382.3 million in the first quarter of 2024. Care Delivery segment revenue increased by 9% to $33.4 million, while the segment's operating loss grew to $3.1 million from $0.2 million in the first quarter of 2024. * Care Enablement segment revenue rose by 19% to $39.6 million, with operating income remaining relatively stable at $3.5 million.

The report also highlighted the company's leadership updates, including the addition of a Chief Data & Analytics Officer, Chief Accounting Officer, and the promotion of a Chief People Officer. Additionally, Astrana Health's pending acquisition of Prospect Health received Hart-Scott-Rodino approval and is expected to close in the summer.

The 10-Q report provides a detailed breakdown of the company's financial performance and operational metrics, offering investors and stakeholders valuable insights into Astrana Health's business activities and growth strategies. The market has reacted to these announcements by moving the company's shares 4.03% to a price of $33.435. Check out the company's full 10-Q submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.